<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36697">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01751321</url>
  </required_header>
  <id_info>
    <org_study_id>40591</org_study_id>
    <nct_id>NCT01751321</nct_id>
  </id_info>
  <brief_title>Glucose Variability With DPP-4 Inhibition</brief_title>
  <official_title>Glucose Variability With DPP-4 Inhibition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scientific Clinical Center of OJSC Russian Railways</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scientific Clinical Center of OJSC Russian Railways</source>
  <oversight_info>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glucose Variability With DPP-4 Inhibition
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with Type 2 Diabetes, age 35-75y., will be included in this double blind randomized
      placebo controlled study.

      The sample size of 50  patients completing the 30 day study period is based on statistical
      input from Merck Research Laboratories, Rahway NJ.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">October 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>glucose variability</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>sitagliptin, metformin, placebo</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>group- 25 patients will take sitagliptin 50 mg  and metformin 1000 mg twice in a day
group- 25 patients will take placebo 50 mg and metformin 1000 mg twice in a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin, placebo</intervention_name>
    <description>sitagliptin 50 / metformin 1000 twice in a day and placebo 50 mg /metformin 1000 twice in a day</description>
    <arm_group_label>sitagliptin, metformin, placebo</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes

          -  receiving a stable dose of metformin  â‰¥ 1500 mg

          -  HbA1c 7,5% -10/0 %

        Exclusion Criteria:

          -  Type 1 diabetes

          -  HbA1c &lt; 7,5% and &gt; 10,0%
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Ametov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scientific Clinical Center of OJSC Russian Railways</affiliation>
  </overall_official>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 13, 2012</lastchanged_date>
  <firstreceived_date>December 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sitagliptin</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
